The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.
A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.
Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.
Topical finasteride is considered safer for the liver than oral finasteride due to less systemic absorption, but regular liver function tests are advised. The user is concerned about liver health due to a history of NAFLD and is exploring topical finasteride as a safer alternative.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.
The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.
A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.
The conversation discusses changes in scalp texture and appearance in areas of hair loss, with concerns about the suitability of these areas for hair transplants. Users mention issues like fibrosis, inflammation, and thinner skin, advising caution and consultation with clinics before proceeding with transplants.
The user experienced noticeable hairline regrowth after starting finasteride for crown hair loss, despite scalp irritation from topical minoxidil. They are impatient for crown results.
The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.
The daily regimen includes oral finasteride, topical minoxidil, and witch hazel toner to reduce itchiness. Witch hazel is noted for its hydrating properties and affordability.
A user is concerned about receding hairlines and considers using finasteride and minoxidil but is hesitant due to potential side effects. Others advise starting treatment early to prevent further hair loss, emphasizing that finasteride is generally safe and effective for prevention.
A user with alopecia areata is considering treatment options like injections or Olumiant but is concerned about cost and whether delaying treatment will lead to permanent hair loss. They are seeking alternative treatments that are more affordable for a college student.
A user is considering switching from oral to topical treatments for hair loss due to side effects like watery semen and erectile dysfunction. They are currently using oral finasteride and minoxidil and are concerned about potential sexual side effects with topical use.
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.
Minoxidil can cause dark circles and skin issues, and users suggest reducing dosage or switching to foam. Supplements like vitamin C, glycine, and MSM may help with collagen production to reduce these side effects.
The conversation discusses skepticism towards unconventional hair loss remedies, emphasizing the effectiveness of proven treatments like oral DHT blockers, topical minoxidil, and finasteride. It criticizes misleading advice and highlights the importance of starting effective treatments early.
A user created a web app called TrichoMetrics to track hair loss using photos and metrics like density and thinning. The app supports tracking treatments like Minoxidil and finasteride, with features for setting baselines, comparing progress, and logging treatment adherence.
Balding's emotional impact is discussed, highlighting self-acceptance and well-being. Treatments like finasteride, minoxidil, and microneedling are mentioned, but the focus is on self-care and maintaining perspective.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
Topical retinol does not affect hair loss and may help hair regrowth. It is different from isotretinoin, which can cause hair loss due to its systemic effects.
Topical dutasteride residue on pillows may cause ear redness and irritation. The user is concerned about a contact reaction from the treatment transferring to the pillow.
The conversation is about hair loss and the effectiveness of treatments like finasteride, with one user expressing satisfaction after seeing hair regrowth on CCTV. Other users share their experiences with hair visibility and discuss the effectiveness of finasteride compared to dutasteride.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.